Equities

Japan Medical Dynamic Marketing Inc

Japan Medical Dynamic Marketing Inc

Actions
Health CareMedical Equipment and Services
  • Price (JPY)627.00
  • Today's Change-10.00 / -1.57%
  • Shares traded68.90k
  • 1 Year change-31.25%
  • Beta0.9903
Data delayed at least 20 minutes, as of May 21 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Japan Medical Dynamic Marketing, INC. is a Japan-based medical equipment provider. The Company is principally engaged in the import, development, manufacture and sale of medical equipment primarily in the field of orthopedic surgery. The Company has two segments. The Japan segment imports materials for osteosynthesis, artificial joints and spinal fixation devices from manufacturers, and sell them in Japan. The America segment is involved in the development and manufacture of materials for osteosynthesis, artificial joints, spinal fixation devices and other products, as well as the sale of medical equipment in North America. As of March 31, 2014, the Company had one subsidiary in the United States.

  • Revenue in JPY (TTM)23.18bn
  • Net income in JPY1.27bn
  • Incorporated1973
  • Employees488.00
  • Location
    Japan Medical Dynamic Marketing Inc12-2, Ichigayadai-machiSHINJUKU-KU 162-0066JapanJPN
  • Phone+81 333416545
  • Fax+81 333416752
  • Websitehttps://www.jmdm.co.jp/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Create Medic Co Ltd12.69bn83.34m9.29bn962.00104.670.572413.450.73189.189.181,395.571,678.910.66781.734.3913,193,190.000.43853.000.51453.5343.6845.360.65674.602.98--0.050363.222.103.11-68.06-25.530.66271.12
DVx Inc45.85bn172.91m10.82bn319.0060.461.1417.890.23616.6116.614,394.81880.721.9826.604.02--0.74743.111.777.5710.3911.600.37711.491.51--0.001447.57-3.442.57-81.53-29.2311.2315.81
JMS Co Ltd65.29bn-36.00m13.33bn5.65k--0.32524.740.2042-1.49-1.492,668.181,657.260.82072.784.07---0.05781.33-0.08651.9721.5924.29-0.07051.570.987--0.397943.412.432.38-112.81---2.421.22
OLBA Healthcare Holdings Inc117.02bn1.50bn13.68bn1.32k8.741.2010.780.1169250.44250.4419,539.551,826.782.6616.204.3288,854,800.003.402.7112.139.7811.5811.061.280.91740.9764152.760.162732.162.330.5165-7.896.06-6.4211.84
Techno Medica Co Ltd10.28bn1.35bn15.45bn225.009.720.882521.191.50181.53181.531,319.311,998.920.55772.552.65--7.316.688.787.8050.1048.8613.1112.313.85----39.339.781.9617.154.190.71687.67
Japan Medical Dynamic Marketing, INC.23.18bn1.27bn16.87bn488.0013.190.65765.810.727648.3048.30880.53968.740.76090.68154.15--4.296.514.927.5363.6966.975.638.882.11--0.055218.268.786.74-10.68-8.52-2.959.24
HOSHI IRYO-SANKI CO., LTD14.78bn1.39bn17.37bn470.0011.360.92737.511.18447.23447.234,742.975,478.130.667434.485.35--6.375.668.077.1948.7849.049.558.652.86--0.045815.747.256.4211.159.87-13.238.45
Daiken Medical Co Ltd9.75bn988.60m17.48bn188.0015.952.2514.531.7934.4134.41339.39244.440.88563.914.03--8.987.4412.9110.8440.8441.7410.149.281.58752.550.23171.356.713.0138.843.03-4.010.9806
Seed Co Ltd32.40bn1.96bn17.71bn974.007.601.023.690.546576.9476.941,276.55573.500.72332.657.48--4.381.997.533.5143.7842.316.062.740.8037--0.578139.565.891.90721.4415.3020.424.56
Medius Holdings Co Ltd250.78bn847.94m18.60bn2.29k21.810.93647.160.074238.5138.5111,407.31897.032.2717.994.25109,607,600.000.76731.643.176.0212.0511.490.33810.58370.899338.740.565731.155.497.29-19.8015.0942.529.46
Japan Tissue Engineering Co., Ltd.2.51bn143.17m24.85bn215.00173.594.0989.659.893.533.5361.91149.730.36253.534.26--2.06-4.722.37-5.3167.2457.305.69-16.385.85996.59----23.701.29119.63--30.22--
Data as of May 21 2024. Currency figures normalised to Japan Medical Dynamic Marketing Inc's reporting currency: Japanese Yen JPY

Institutional shareholders

16.55%Per cent of shares held by top holders
HolderShares% Held
Newton Investment Management Japan Ltd.as of 31 Jul 20231.07m4.04%
Rheos Capital Works, Inc. (Investment Management)as of 30 Sep 2022856.10k3.23%
Nomura Asset Management Co., Ltd.as of 30 Apr 2024550.30k2.08%
Sumitomo Mitsui DS Asset Management Co., Ltd.as of 09 May 2024449.80k1.70%
The Vanguard Group, Inc.as of 09 May 2024375.50k1.42%
Dimensional Fund Advisors LPas of 09 May 2024299.61k1.13%
Nikko Asset Management Co., Ltd.as of 10 May 2024239.70k0.91%
Daiwa Asset Management Co. Ltd.as of 29 Mar 2024221.30k0.84%
Norges Bank Investment Managementas of 31 Dec 2023185.00k0.70%
Mitsubishi UFJ Asset Management Co., Ltd.as of 10 May 2024133.50k0.50%
More ▼
Data from 31 Dec 2023 - 13 May 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.